Clinical trials | IRCCS - Istituto Nazionale dei Tumori

INFO & CONTACTS: +39 02 2390 1

Search

Search

Follow us on

Clinical trials

Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breastand colorectal cancers

Phase: Phase I clinical trials

Principal Investigator: Dott. Maccauro Marco

Main Facility: Nuclear Medicine

Drug: [177Lu]Lu-NNS309
A phase I study to evaluate the safety and preliminary signs of efficacy of [177Lu]Lu-OncoFAP-23 alone or in combination with L19-IL2 as a treatment of metastatic FAP-positive solid tumors

Phase: Phase I clinical trials

Main Facility: Nuclear Medicine

Drug: [68Ga]Ga-OncoFAP (OncoFAP-DOTAGA marcato con 68Ga)

[177Lu]Lu-OncoFAP-23 (OncoFAP-23 marcato con 177Lu)

L19-IL2
A Phase 1 First-in-Human Study of the Safety and Efficacy of IMC-P115C as a Single Agent and in Combination with Standard of Care Agents in HLA-A*02:01 Positive Participants with Advanced PRAME Positive Cancers

Phase: Phase I clinical trials

Principal Investigator: Dr. Di Nicola Massimo

Main Facility: Phase 1 Clinical Trials Unit (Early Clinical Drug Development Team – ECDD)

Drug: IMC-P115C, Bevacizumab, Olaparib, pembrolizumab/carboplatin/paclitaxel/pemetrexed, ipilimumab/nivolumab
A first-in-human study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor, in participants with MTAP-delet

Phase: Phase I clinical trials

Principal Investigator: Dott. Duca Matteo

Main Facility: Medical Oncology 1

Drug: BAY 3713372